cytarabine

Ligand id: 4827

Name: cytarabine

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 8
Hydrogen bond donors 5
Rotatable bonds 2
Topological polar surface area 128.28
Molecular weight 244.09
XLogP -1.89
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Cytarabine is used to treat some types of leukemia including leukemia associated with meningitis. In August 2017 the US FDA approved a fixed-dose combination of cytarabine and daunorubicin (Vyxeos®) for the treatment of adults with two types of acute myeloid leukemia (AML): newly diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Mechanism Of Action and Pharmacodynamic Effects
Cytarabine is toxic to proliferating mammalian cells as it causes DNA damage during the S phase of cell division, most likely by inhibiting the activity of DNA polymerases. Some evidence suggests direct incorporation of cytarabine into DNA and RNA, again leading to nucleic acid damage. Due to the complex and varied nature of nucleic acids we do not include DNA or RNA as targets on this database.
External links